MEA Diabetes Market

ID: MRFR/Pharma/2185-HCR
65 Pages
Satyendra Maurya
Last Updated: June 08, 2026
Middle East and Africa Diabetes Market Research Report Information By Type (Type 1, Type 2, and Gestational Diabetes), By Test (Random Blood Sugar Test, Fasting Blood Sugar Test, Oral Glucose Tolerance Test, Initial Glucose Challenge Test, and Others), By Device (Blood Glucose Monitoring Devices, Diabetes Management Devices, and Others), By Treatment (Medications, Insulin Therapy, Transplantation, Bariatric Surgery, Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
MEA Diabetes Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.93%
2024 Market Size$ 0.69 Billion
2025 Market Size$ 0.73 Billion
2035 Market Size$ 1.29 Billion
Key Players
Novo Nordisk
Sanofi
Boehringer Ingelheim
AstraZeneca
Merck & Co.
Johnson & Johnson
Trends
  • Rising Prevalence of Diabetes
  • Technological Advancements in Diabetes Care
  • Government Initiatives and Policies
Opportunities
  • Rising Healthcare Expenditure
  • Enhanced Regulatory Frameworks
  • Increasing Awareness and Education
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type of Diabetes (USD Billion)
      1. 4.1.1 Type 1 Diabetes
      2. 4.1.2 Type 2 Diabetes
      3. 4.1.3 Gestational Diabetes
      4. 4.1.4 LADA Diabetes
      5. 4.1.5 MODY Diabetes
    2. 4.2 Healthcare, BY Treatment Method (USD Billion)
      1. 4.2.1 Insulin Therapy
      2. 4.2.2 Oral Medications
      3. 4.2.3 Dietary Management
      4. 4.2.4 Physical Activity
      5. 4.2.5 Continuous Glucose Monitoring
    3. 4.3 Healthcare, BY Patient Demographics (USD Billion)
      1. 4.3.1 Children
      2. 4.3.2 Adults
      3. 4.3.3 Elderly
      4. 4.3.4 Pregnant Women
      5. 4.3.5 Obese Individuals
    4. 4.4 Healthcare, BY Complications (USD Billion)
      1. 4.4.1 Cardiovascular Disease
      2. 4.4.2 Neuropathy
      3. 4.4.3 Nephropathy
      4. 4.4.4 Retinopathy
      5. 4.4.5 Foot Ulcers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novo Nordisk (DK)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sanofi (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boehringer Ingelheim (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Johnson & Johnson (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Abbott Laboratories (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Eli Lilly and Company (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 MEA MARKET ANALYSIS BY TYPE OF DIABETES
    3. 6.3 MEA MARKET ANALYSIS BY TREATMENT METHOD
    4. 6.4 MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    5. 6.5 MEA MARKET ANALYSIS BY COMPLICATIONS
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY TYPE OF DIABETES, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY TYPE OF DIABETES, 2024 TO 2035 (USD Billion)
    14. 6.14 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
    16. 6.16 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    18. 6.18 HEALTHCARE, BY COMPLICATIONS, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY COMPLICATIONS, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE OF DIABETES, 2026-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT METHOD, 2026-2035 (USD Billion)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
      4. 7.2.4 BY COMPLICATIONS, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

MEA Diabetes Market Segmentation

MEA Diabetes Market By Type of Diabetes (USD Billion, 2026-2035)

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • LADA Diabetes
  • MODY Diabetes

MEA Diabetes Market By Treatment Method (USD Billion, 2026-2035)

  • Insulin Therapy
  • Oral Medications
  • Dietary Management
  • Physical Activity
  • Continuous Glucose Monitoring

MEA Diabetes Market By Patient Demographics (USD Billion, 2026-2035)

  • Children
  • Adults
  • Elderly
  • Pregnant Women
  • Obese Individuals

MEA Diabetes Market By Complications (USD Billion, 2026-2035)

  • Cardiovascular Disease
  • Neuropathy
  • Nephropathy
  • Retinopathy
  • Foot Ulcers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.